Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-99
SponsorYale University
About this trial
This study seeks to determine the feasibility, acceptability, and preliminary efficacy of an intervention consisting of off-label use of a medication with strong efficacy data for alcohol use disorder (AUD) with medical management and a clinical pharmacist-delivered behavioral intervention in reducing alcohol use among individuals with HIV and AUD.
Eligibility criteria
Qualifiers
diagnosed with HIV
Receive care at the Atlanta VA Healthcare System
Age 18 or over
Meet criteria for mild, moderate, or severe alcohol use disorder by the DSM-5 Alcohol Symptom Checklist and the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) screen
Disqualifiers
Active engagement in formal alcohol treatment including medications for alcohol use disorder at the time of enrollment
Self-report or laboratory test confirming pregnancy, nursing, or trying to conceive
Life-threatening or unstable medical, surgical, or psychiatric condition that prohibits participation (including current or past intent to harm oneself or others within the prior 12 months and not receiving treatment)
Untreated moderate to severe opioid use disorder
Trial design
Treatments tested in this trial
- semaglutide
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Yale University
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Collaborator
Source ClinicalTrials.gov